Arcus Biosciences, Inc.
RCUS
$8.62
$0.111.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,700.00% | -16.05% | -29.58% | -24.00% | 95.00% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 100.00% | 0.00% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.11% | 0.00% | -6.25% | 0.00% | 100.00% |
| Change in Net Operating Assets | 0.00% | 4.17% | 1,222.22% | -- | 2.63% |
| Cash from Operations | -6,500.00% | -13.64% | 141.27% | -64.91% | 97.96% |
| Capital Expenditure | 75.00% | 83.33% | 90.00% | 100.00% | -33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.00% | 52.94% | -233.33% | 103.23% | -225.00% |
| Cash from Investing | 118.93% | 82.14% | -363.64% | 142.31% | -231.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -37.99% | 0.00% | -66.67% | -86.96% | 22,800.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.99% | -166.67% | 700.00% | -91.30% | 22,800.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.59% | 10.53% | 197.83% | -262.50% | 81.25% |